User:Mr. Ibrahem/Axitinib

Axitinib, sold under the brand name Inlyta, is a medication used to treat renal cell cancer (RCC). It is used in advanced disease, either alone or with avelumab or pembrolizumab. It increased time to getting worse to 6.7 months from 4.7 months in those taking sorafenib. It is taken by mouth.

Common side effects include diarrhea, high blood pressure, tiredness, nausea, weight loss, weakness, and constipation. Other side effects may include blood clots, bleeding, heart failure, gastrointestinal perforation, low thyroid, poor wound healing, liver problems, and reversible posterior leukoencephalopathy syndrome (RPLS). Use in pregnancy may harm the baby. It is a tyrosine kinase inhibitor that blocks vascular endothelial growth factor (VEGF).

Axitinib was approved for medical use in the United States and Europe in 2012. In the United Kingdom 4 weeks of treatments costs the NHS about £3,500 as of 2021. In the United States this amount costs about 17,300 USD.